That could be problematic for the high risk groups that are the prime target for the PFE regimen given it increases the half-life and increases levels of other drugs patients tested.
I wonder if ENTA will be adding a longer regimen for one of its EDP-235 phase 2/3 trials?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.